Inactive Instrument

Magle Chemoswed Holding AB (publ) Stock Nasdaq Stockholm

Equities

SE0014401014

Pharmaceuticals

Sales 2024 * 189M 17.23M Sales 2025 * 206M 18.79M Capitalization 326M 29.68M
Net income 2024 * 24M 2.18M Net income 2025 * 30M 2.73M EV / Sales 2024 * 1.95 x
Net Debt 2024 * 42.5M 3.87M Net cash position 2025 * - 0 EV / Sales 2025 * 1.58 x
P/E ratio 2024 *
13.7 x
P/E ratio 2025 *
30.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 21.39%
More Fundamentals * Assessed data
Dynamic Chart
Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023 CI
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million. CI
Magle Chemoswed Holding AB Proposes Dividend for the Fiscal Year 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Magle Group Enters Collaboration with Sirtex Medical to Support the International Commercialization of Embocept S Dsm 50 Um CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Magle Group Announces Positive Results from Post-Market Clinical Follow-Up of SmartPAN CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait CI
Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina CI
Magle Chemoswed Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 51 14-12-31
Director of Finance/CFO - 20-06-30
Chief Operating Officer 48 98-12-31
Members of the board TitleAgeSince
Director/Board Member 78 15-12-31
Director/Board Member 79 15-12-31
Director/Board Member 44 19-12-31
More insiders
Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
Calendar
More about the company